| TORC - resTORbio Inc (Healthcare: Biotechnology) | Projected Earnings Date: 0000-02-29 (Delayed quote data 2026-02-10) |
|
|
|||||||||||||||||
|
|
|
| Company Profile | |
| resTORbio Inc is a clinical-stage biopharmaceutical company. It mainly focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. The company focuses on the mechanistic target of rapamycin (mTOR) pathway which regulates aging, and specifically on selective inhibition of the target of rapamycin complex 1. It is also involved in the development of RTB101 which is a small molecule, potent TORC1 inhibitor. The company's pipeline products include RTB101 and RTB101+ everolimus. | |
| Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. |